Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron for prevention of chemotherapy-induced acute and delayed vomiting (real-world study)
ChiCTR2500109367Phase 4Not yet recruiting
- Sponsor
- Xuzhou Mining Group General Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of palonosetron in cancer and chemotherapy-induced nausea and vomiting (CINV), sponsored by Xuzhou Mining Group General Hospital. Primary endpoint: Complete relief rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
palonosetron
03
Conditions
cancerchemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on ChiCTR2500109367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109367.